These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 186408)

  • 21. A poliovirus-susceptible transgenic mouse model as a possible replacement for the monkey neurovirulence test of oral poliovirus vaccine.
    Dragunsky E; Taffs R; Chernokhvostova Y; Nomura T; Hioki K; Gardner D; Norwood L; Levenbook I
    Biologicals; 1996 Jun; 24(2):77-86. PubMed ID: 8889053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diplovax. A new oral polio vaccine.
    Med Lett Drugs Ther; 1972 Aug; 14(16):57-8. PubMed ID: 4346222
    [No Abstract]   [Full Text] [Related]  

  • 23. Transgenic mice as an alternative to monkeys for neurovirulence testing of live oral poliovirus vaccine: validation by a WHO collaborative study.
    Dragunsky E; Nomura T; Karpinski K; Furesz J; Wood DJ; Pervikov Y; Abe S; Kurata T; Vanloocke O; Karganova G; Taffs R; Heath A; Ivshina A; Levenbook I
    Bull World Health Organ; 2003; 81(4):251-60. PubMed ID: 12764491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Studies on the neurovirulence of the attenuated poliovirus type 3 (USOL-D) in monkey experiments].
    Unterharnscheidt F; Simon J; Bonin O; Günther O; Schmidt K; Schmidt I; Heber L; von Mettenheim A
    Arb Paul Ehrlich Inst Georg Speyer Haus Ferdinand Blum Inst Frankf A M; 1966; 62():1-19. PubMed ID: 4287917
    [No Abstract]   [Full Text] [Related]  

  • 25. Neurovirulence tests of type 3 oral poliovirus vaccine manufactured by Lederle Laboratories, 1964-1988.
    Nathanson N; Horn SD
    Vaccine; 1992; 10(7):469-74. PubMed ID: 1609550
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Studies on neurovirulence in poliovirus-sensitive transgenic mice and cynomolgus monkeys for the different temperature-sensitive viruses derived from the Sabin type 3 virus.
    Abe S; Ota Y; Doi Y; Nomoto A; Nomura T; Chumakov KM; Hashizume S
    Virology; 1995 Jun; 210(1):160-6. PubMed ID: 7793068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Ultrastructural changes in the central nervous system of monkeys in poliomyelitis].
    Erman BA; Tulakina LG
    Arkh Patol; 1976; 38(10):64-70. PubMed ID: 190980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of candidates for new type 2 and type 3 oral poliovirus vaccines.
    Kohara M; Abe S; Yoshioka I; Nomoto A
    Dev Biol Stand; 1993; 78():141-8. PubMed ID: 8388824
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A poliomyelitis model through mucosal infection in transgenic mice bearing human poliovirus receptor, TgPVR21.
    Nagata N; Iwasaki T; Ami Y; Sato Y; Hatano I; Harashima A; Suzaki Y; Yoshii T; Hashikawa T; Sata T; Horiuchi Y; Koike S; Kurata T; Nomoto A
    Virology; 2004 Mar; 321(1):87-100. PubMed ID: 15033568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Studies on new attenuated strains of type III live poliomyelitis vaccine. II. Field trials of Zhong III2 virus.
    Chin Med J (Engl); 1980 Sep; 93(9):591-8. PubMed ID: 6253237
    [No Abstract]   [Full Text] [Related]  

  • 31. A new type 3 attenuated poliovirus for possible use in oral poliovirus vaccine.
    Vonka V; Janda Z; Simon J; Adam E; Stárek M
    Prog Med Virol; 1967; 9():204-55. PubMed ID: 4293687
    [No Abstract]   [Full Text] [Related]  

  • 32. Development of a neurovirulent testing system for oral poliovirus vaccine with transgenic mice.
    Levenbook I; Nomura T
    Lab Anim Sci; 1997 Apr; 47(2):118-20. PubMed ID: 9150487
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of the new control methods for oral poliomyelitis vaccine.
    Grachev VP; Karganova GG; Rumyantsev AA; Ivanova OE; Eremeeva TP; Drozdov SG
    Dev Biol (Basel); 2001; 105():211-7. PubMed ID: 11763330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transgenic mice carrying the human poliovirus receptor: new animal models for study of poliovirus neurovirulence.
    Horie H; Koike S; Kurata T; Sato-Yoshida Y; Ise I; Ota Y; Abe S; Hioki K; Kato H; Taya C
    J Virol; 1994 Feb; 68(2):681-8. PubMed ID: 8289371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The assessment of OPV vaccines by the monkey neurovirulence test: why and how to qualify the experts in histology of central nervous system.
    Poirier B; Morgeaux S; Fuchs F
    Vaccine; 2002 Nov; 21(1-2):115-9. PubMed ID: 12443669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reflections on the qualitative and quantitative aspects of neurovirulence of different polioviruses.
    Sabin AB
    Dev Biol Stand; 1993; 78():3-7. PubMed ID: 8388830
    [No Abstract]   [Full Text] [Related]  

  • 37. Bilateral substantia nigra involvement in vaccine-associated poliomyelitis.
    França MC; Schmutzler KM; Garibaldi SG; Zanardi VA; Nucci A
    Neurology; 2006 May; 66(10):1597-8. PubMed ID: 16717231
    [No Abstract]   [Full Text] [Related]  

  • 38. Transgenic PVR Tg-1 mice for testing of poliovirus type 3 neurovirulence: comparison with monkey test.
    Dragunsky E; Gardner D; Taffs R; Levenbook I
    Biologicals; 1993 Sep; 21(3):233-7. PubMed ID: 8117436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ethical and safety considerations for the use in clinical trials of new attenuated poliovirus strains.
    Horaud F
    Dev Biol Stand; 1993; 78():149-54; discussion 154-5. PubMed ID: 8388825
    [No Abstract]   [Full Text] [Related]  

  • 40. Experimental poliomyelitis in bonnet monkey. Clinical features, virology and pathology.
    Samuel BU; Ponnuraj E; Rajasingh J; John TJ
    Dev Biol Stand; 1993; 78():71-8. PubMed ID: 8388833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.